The DEA and HHS have jointly granted a critical one-year extension of telemedicine prescribing flexibilities for controlled substances, ensuring uninterrupted access to essential medications for patients across the U.S. This fourth temporary rule, published in the Federal Register on December 31, 2025, extends the COVID-19 public health emergency waivers through December 31, 2026averting potential chaos from their scheduled expiration.

Under the extension:

Practitioners can continue prescribing Schedule II–V controlled substances remotely via telemedicine (audio-video required for most, with audio-only permitted for specific opioid use disorder treatments).

No prior in-person evaluation is needed, preserving flexibility introduced in 2020.

This applies alongside two new final rules effective December 31, 2025 one expanding buprenorphine induction via telemedicine and another ensuring continuity for VA patients.

The decision responds to stakeholder warnings of disrupted care especially for vulnerable groups like rural residents, seniors, those with disabilities, and individuals managing mental health or addiction. Without extension, abrupt reversion to pre-pandemic Ryan Haight Act requirements (mandating in-person visits) could limit access and exacerbate shortages.

This temporary measure buys time for finalizing permanent regulations, including the proposed Special Registration for Telemedicine (comment period yielded thousands of inputs). It balances expanded access with safeguards against diversion, aligning with broader efforts to modernize telehealth while protecting public safety.

Industry reactions highlight relief: Advocacy groups praise avoided disruptions, while providers gain breathing room to adapt workflows. The extension also supports ongoing transitions to compliant platforms amid evolving reimbursement and state laws.

As telehealth solidifies as a mainstay post-pandemic utilization remains elevated this extension sustains momentum toward equitable, technology-enabled care.